WHO ICTRP trial
Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone…
JPRN-jRCT2080223906 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080223906 |
|---|---|
| Public title | Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency |
| Scientific title | A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, 12-MONTH, EFFICACY AND SAFETY STUDY OF WEEKLY MOD-4023 COMPARED TO DAILY GENOTROPIN THERAPY IN JAPANESE PRE-PUBERTAL CHILDREN WITH GROWTH HORMONE DEFICIENCY |
| Primary sponsor | OPKO Health Inc. (ICCC: EPS Corporation) |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Japan |
| Conditions | Treatment of children with growth failure due to growth hormone deficiency (GHD) |
| Interventions | investigational material(s) Generic name etc : Somatrogon (Genetical Recombination) INN of investigational material : somatrogon Therapeutic category code : 241 Pituitary hormone preparations Dosage and Administration for Investigational… |
| Registration date | May 17, 2018 |
| Target size | 44 |
| Secondary IDs | NCT03874013;JapicCTI-183963 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: